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The heterogeneous and invasive nature of pediatric gliomas poses significant treatment
challenges, highlighting the importance of identifying novel chemotherapeutic targets.
Recently, recurrent Fibroblast growth factor receptor 1 (FGFR1) mutations in pediatric
gliomas have been reported. Here, we explored the clinical relevance of FGFR1
expression, cell migration in low and high grade pediatric gliomas and the role of
FGFR1 in cell migration/invasion as a potential chemotherapeutic target. A high density
tissue microarray (TMA) was used to investigate associations between FGFR1 and
activated phosphorylated FGFR1 (pFGFR1) expression and various clinicopathologic
parameters. Expression of FGFR1 and pFGFR1 were measured by immunofluorescence
and by immunohistochemistry (IHC) in 3D spheroids in five rare patient-derived pediatric
low-grade glioma (pLGG) and two established high-grade glioma (pHGG) cell lines.
Two-dimensional (2D) and three-dimensional (3D) migration assays were performed for
migration and inhibitor studies with three FGFR1 inhibitors. High FGFR1 expression was
associated with age, malignancy, tumor location and tumor grade among astrocytomas.
Membranous pFGFR1 was associated with malignancy and tumor grade. All glioma
cell lines exhibited varying levels of FGFR1 and pFGFR1 expression and migratory
phenotypes. There were significant anti-migratory effects on the pHGG cell lines with
inhibitor treatment and anti-migratory or pro-migratory responses to FGFR1 inhibition
in the pLGGs. Our findings support further research to target FGFR1 signaling in
pediatric gliomas.
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INTRODUCTION
Pediatric and adult gliomas are now recognized to be distinct disease entities. However, current
standard of care for adult and pediatric high grade glioma (HGG) remains the same and both are
associated with dismal disease outcome. Pediatric and adult gliomas are clearly distinct biologically,
with differences in location, transformation rate [from low grade gliomas (LGG) to HGGs] and
differences in tumor biology and genetic drivers (1). Pediatric glioma drug development must be
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based on a new understanding of the unique biology of these
tumors, rather than simply employing adult drug strategies.
Pediatric LGGs are strikingly characterized by oncogenic
mutations in the BRAF gene leading to constitutive BRAF
kinase activity (2). In vivo studies to target BRAF mediated
signaling in other tumor types as well as first clinical trials
in pediatric oncology have highlighted the importance of
combination treatment targeting BRAF driven signaling (3,
4), one of such potential additional targets is the fibroblast
growth factor receptor 1 (FGFR1). So far, there has been very
little research into FGFRs in pediatric low and high grade
gliomas. FGFRs comprise a group of membrane receptors
involved in many cellular processes including proliferation and
migration. High FGFR1 expression levels have been documented
in many cancers including bladder and lung cancer due to
gene amplification or deregulation at the transcriptional level
(5, 6). In pediatric gliomas, genomic analyses have reported
recurrent FGFR1 mutations (5, 6). Jones et al. sequenced blood
and tumor tissues from pilocytic astrocytomas and identified
FGFR1 mutations (7) with the mutational hotspots located
on codons Asn546 and Lys656 (7, 8). Becker et al. reported
that 6.7% of pilocytic tumors had FGFR1 point mutations on
Lys656 and subsequently that tumors carrying the mutation
had significantly poorer prognoses compared to wild-type
variants (9). These studies support exploring FGFR1 as a
potential genetic driver in pediatric glioma tumorigenesis (7,
8) and as a druggable target. All recent studies in pediatric
glioma research have focused on FGFR1 at the genomic
level with very little known about the role of FGFR at the
protein level. Additionally, studies on FGFR1 and FGFR1
mutations have mainly concentrated on pediatric LGGs and
further research is needed in pediatric HGGs (10, 11). This
study aimed to firstly investigate FGFR1 and activated FGFR1
(pFGFR1) expression at the protein level in patient samples
including pediatric and adult neurological malignancies where
we identified an association of expression levels for FGFR1
and protein localization for pFGFR1 and malignancy. We
screened patient derived and established pLGG and pHGG
cell lines for the FGFR1 reported mutational hotspots and
determined FGFR1 and pFGFR1 protein expression levels.
We also studied the migratory/invasive behavior of low grade
pediatric astrocytomas in comparison to HGGs since this
is a prerequisite of disease progression. Finally, we assessed
the role of FGFR1 protein expression and signaling in these
processes with FGFR1 inhibitor studies. Our findings support
a role for FGFR1 signaling in pediatric glioma migration with
a potential for kinase signaling targeting: our TMA studies
indicated an association of FGFR1 expression and malignancy
and tumor grade; membranous pFGFR1 localization was also
associated with malignancy and grade. Cell lines with high
FGFR1 expression levels of both FGFR1 and activated FGFR1
possessed advanced migratory abilities. FGFR1 inhibitors had
an anti-migratory effect on the two HGG cell lines whereas we
observed an anti-migratory or potentially pro-migratory effect
among the LGG cell lines. As all cell lines were FGFR1 wildtype
we propose that FGFR1 amplification alone may contribute to
disease progression.
MATERIALS AND METHODS
Cell Lines
The established pediatric HGG cell lines SF188 (grade IV, GBM)
and KNS42 (grade IV, GBM) were used. Five rare pediatric LGG
patient-derived cell lines were studied including IN1591, IN2017,
IN2356, IN2688, and IN1520. These cell lines were generated
from grade I pilocytic astrocytomas obtained with informed
consent during debulking surgery (REC 04/Q0508/98). The age
of the patients ranged from 2 to 7 years at diagnosis. There
were 1 female and 4 male patients. Tumor locations included
temporal parietal lobe, frontoparietal lobe, posterior fossa, and
the cerebellum. Patient-derived cell lines were immediately
prepared in the laboratory from approximately 10mg of excised
biopsy, directly adjacent to tumor tissue processed for routine
histological evaluation tissue as previously described (12). Cells
were used for experiments between passages 1–4.
All cell lines were verified by in-house short tandem repeat
(STR) profiling service and were mycoplasma free.
Cell Culture
KNS42 and SF188 were grown in complete Dulbecco’s Modified
Eagle’s Medium (DMEM) (Sigma) supplemented with 10% heat-
inactivated fetal calf serum (HI-FCS) (Labtech) as previously
described (13). IN1591, IN2017, IN2356, IN2688, and IN1520
were grown in Ham’s F-10 Nutrient mixture (1X) (Gibco)
supplemented only with 10% HI-FCS (Labtech). F-10 medium
was the preferred choice for the patient derived samples as the
glucose concentration was more comparable to in vivo glucose
levels but medium composition did not significantly differ
otherwise. Global expression profiling had demonstrated that
short-term cultures derived from pediatric pilocytic astrocytoma
are representative of the tumors in situ when grown with
serum (14). The cells were passaged at 1:2 to 1:3 dilutions
weekly or bimonthly.
Inhibitors
The inhibitors used were Ponatinib (Selleckchem), SSR128129E
(Selleckchem), and BGJ398 (Selleckchem). All inhibitors were
diluted in dimethylsulphoxide (DMSO) (Sigma).
Screening for FGFR1 and Activated FGFR1
(pFGFR1) Expression Levels in the Tissue
Microarray (TMA)
A commercially available tissue microarray (TMA) (CNS2081,
US Biomax) with 208 cores obtained from CNS pathologies
was screened for FGFR1 and pFGFR1 expression by
immunohistochemistry (IHC). The TMA included adult and
pediatric HGGs, LGGs, meningiomas, and medulloblastomas
alongside healthy controls. Prior to staining, the TMA slide
was heated at 70◦C before immersion in xylene. Rehydration
in absolute ethanol (Sigma) was followed by 90% ethanol and
finally 70% ethanol. Enzyme antigen retrieval was achieved
using Bond Enzyme Pre-treatment Kit (Leica Biosystems).
Endogenous peroxidase activity was blocked using Bloxall
(Vector Laboratories). Protein blocking was then performed
with 10x casein (1:10) (Vector Laboratories). Rabbit anti-FGFR1
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primary antibody (Sigma) or anti pFGFR1 (Cell signaling)
was added at 1:3,000 and 1:100 concentrations followed by
incubation with the anti-rabbit polymer horseradish peroxidase
(HRP) secondary antibody (MenaPath). The slide was developed
with ImmPACT 3,3’-diaminobenzidine (DAB) HRP substrate
(Vector Laboratories) and counterstained using in-houseMayer’s
haematoxylin, dehydrated and mounted with DPX. An Aperio
scanner (Leica Microsystems, Milton Keynes, UK) was used for
visualization and scoring of the stained cores.
Preparation of 3D Spheroids for
Immunohistochemistry
Spheroids embedded in collagen were prepared after completion
of migration/invasion experiments according to Cheng et al. (15).
Sections of spheroids were stained for the expression of Ki67
(proliferation marker) (ThermoScientific), Cleaved caspase 3
(apoptosis marker) (Cell signaling), FGFR1, and pFGFR1 (Sigma,
Cell Signaling).
Immunohistochemistry Scoring
The TMA slides were digitally scanned using in-house virtual
pathology services. Immunostaining was quantified using
manual and computerized techniques. The immunostaining of
each core was scored by eye using two scoring methods; intensity
of staining: 0—no staining, 1—weak staining, 2—medium
staining and 3—strong staining, and counting the number of
cells stained for a marker and expressing as a proportion: 0–
0, 1–25%−1, 26–50%−2, 51–75%−3, 76–100%−4. An overall
score, out of 7, was calculated combining intensity of the
immunostaining and percentage of the core stained. Scores were
dichotomized into low and high FGFR1 expression using STATA
13.1 (StatCorp). For automated scoring, Aperio ImageScope
(Leica Biosystems) was used to generate positive pixel count
image analysis of each TMA core. Pre-set 1,400× 1,400 (width by
height) boxes were used. Each core was analyzed individually and
generated a “positivity” value, which quantified the percentage
of immunopositive staining present. The positive pixel count
percentage was given an overall score, out of 7, using: Positive
Pixel Count Percentage % Score 0–12.5 = 0; 12.6–25 = 1; 26–
37.5 = 2; 37.6–50 = 3; 51–62.5 = 4; 62.6–75 = 5; 76–87.5 = 6;
87.6–100= 7.
STATA 13.1 was used to dichotomize the scores into low and
high FGFR1 expression. The sections containing the spheroids
and migratory cells encased in collagen were analyzed and
confirmed by the pathologist (Azzam Ismail) and the individual
cells within the spheroids identified by their haematoxylin stain.
Identified individual cells within the spheroids were counted
manually and recorded as being stained or not stained with
the individual marker for protein expression. All antibody
concentrations had been pre- optimized using negative and
positive control tissues. Scoring of the spheroid sections was
achieved by counting the number of cells with protein expression
and expressing as % of cells stained, also noting cellular
localization of the marker within the spheroids, for example
nuclear, cytoplasmic and membrane associated. Cleaved caspase
3 and Ki67 were recorded as a proportion of cells scored
and then divided into high (>50% stained) and low (<50%
stained) expression.
Q-PCR Detection of BRAF Fusion
Total RNA was extracted from five patient-derived cell
cultures of pLGG using an RNeasy Mini kit (Qiagen Ltd.,
Manchester, UK) and reverse transcribed to cDNA using
a QuantiTect Reverse Transcription Kit (Qiagen) according
to the manufacturer’s instructions. Q-PCR was performed
using 2.5 µl of cDNA from each culture, primers and
TaqMan probes specific for the KIAA1549-BRAF fusions 16–
9, 15–9, and 16–11 (Assays-on-Demand Gene Expression
products Hs04396516_ft, Hs04421337_ft and Hs04396507_ft)
and TaqMan Gene Expression Mastermix on an ABI 7500 HT
Sequence Detection System (Applied Biosystems, Warrington,
UK). Glyceraldehyde-3- phosphate dehydrogenase (GAPDH)
was used as an endogenous control (Assays-on-Demand Gene
Expression product Hs02758991). Amplification conditions were
2min at 50◦C, 10min at 95◦C, and then 50 cycles of 15 s at
95◦C and 1min at 60◦C. Fluorescence was recorded and cycles
to threshold (CT) were calculated using 7500 Sequence Detection
Software version 2.3 (Applied Biosystems). Reactions were run in
triplicate in singleplex reactions.
DNA Extraction for FGFR1 Mutation
Screening
DNA was extracted from cells using the Qiagen DNeasy kit
according to manufacturer’s instructions.
Mutation Screening of FGFR1 Mutation
Hotspots
PCR primers were designed using Primer3 (http://bioinfo.ut.
ee/primer3-0.4.0/). Primer set F1 targeted codon 546; primer
set F2 targeted codons 655–658 of reference cDNA sequence
NM_023110 with ATGi as codon 1. All primers had binding
sites in the introns flanking the exons containing the target
codons. Primers sequences were: F1F tcaagtcccagggaaaagca;
F1R gggcagggaaagccagtct; F2F gagccttccagctccctcac; F2R
ccaccccactccttgcttct. PCR was carried out using HotStarTaq
master mix (Qiagen) in 10 µl final volume using 40 pmol of each
primer, 10% DMSO and 10 ng of DNA. Reaction conditions
were 95◦C for 15min, 36 cycles of [95◦C, 30 s; 58◦C 30 s; 72◦C,
30 s], followed by 72◦C for 10min and hold at 15◦C. All samples
were bi-directionally sequenced using Big- Dye terminator
chemistry version 1.1 (Applied Biosystems). PCR primers were
used for sequencing. Data collection was performed using an
Applied Biosystems 3130xl Genetic Analyser. Data analysis was
carried out by visual inspection of electropherograms and using
Mutation Surveyor 3.2 (SoftGenetics).
Immunofluorescence of the Cell Lines
Immunofluorescence was used to determine FGFR1 and pFGFR1
expression in 2D monolayers of all cell lines. Cells were
fixed with 4% paraformaldehyde and permeabilized with 0.1%
PBS-Triton-X-100 (Sigma). After blocking with 0.1% Marvel
skimmed milk powder, the cells were incubated with the primary
antibody, rabbit anti-FGFR1 (1/100, Cell Signaling) or mouse
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anti-pFGFR1 primary antibodies (1/500, Novus Biologicals) in
blocking solution. The secondary antibodies, Alexa Fluor 488
anti-rabbit or anti-mouse (1/500, Molecular Probes), were added
at 4 mg/ml alongside Alexa Fluor 594 Phalloidin stain (Molecular
Probes) in blocking solution.
Image Quantification and Analysis
Immunofluorescence images of the cells were generated with
the EVOS imaging system (Advanced Microscopy Group) set
at the same magnification (x40) to allow cell identification
and comparison across the cell lines analyzed. To guide
fluorescence quantification the cells were incubated with the
specific antibody (anti-FGFR1, pFGFR1) and co-stained with
the nuclear marker DAPI (Molecular Probes) and Alexa Fluor
phalloidin 594 (actin) (1/500, Molecular Probes) to highlight the
overall cell morphology for identification of individual cells. For
image acquisition for each specific marker (FGFR1, pFGFR1)
imaging settings (aperture, exposure time) were obtained to allow
fluorescence capturing at optimal exposure, avoiding under or
over-exposure. The same settings were then applied to all cells
to be analyzed within a group, for example, for all cell lines
unstimulated vs. stimulated stained for FGFR1, on the same day
for normalization and to allow comparison of protein levels.
At least 50 cells/antibody/ three repeats were analyzed; for the
LGG cell lines we scored all the cells within a slide due to low
proliferation and for the HGG cell lines at least 200 cells from 4
randomly selected fields within the slide. Fluorescence images of
the cells were captured as .tif images and analyzed using ImageJ
fluorescence quantification. For this, cells were identified by their
actin and DAPI stains and selected for measurements with the
drawing tool. The mean gray value and integrated density were
measured. Background readings within the individual slides were
also taken. The corrected total cell fluorescence (CTCF) was then
calculated by using the following formula: CTCF = Integrated
Density – (Area of selected cell x Mean fluorescence of back
ground readings).
Two-Dimensional Random Cell Migration
For live cell imaging of random cell migration cells were seeded
at 1 × 105/well in flat-bottomed 96 well plates (Nunc) with or
without inhibitor treatment in full medium, serum-free Heparan
sulphate proteoglycan (HSPG) (Sigma) only supplemented
medium or serum-free HSPG/FGF2 supplemented medium.
FGF2 (Sigma) was added at 10 ng/ml and HSPG (Sigma)
at 10µg/ml. Cell migration was imaged with the IncuCyte
ZOOM system (Essen BioScience) over 72 h at hourly intervals
at x10 magnification. Avi formatted movies were analyzed
using ImageJ1.
For SF188 and KNS42, at least 20 cells per condition/recorded
field were identified and random migratory patterns recorded by
tracking individual nuclei with MTrackJ (https://imagescience.
org/meijering/software/mtrackj/) to determine velocity and
directionality (16). For pLGG, up to 10 cells/condition/field were
identified because of low cell proliferation rates. Rose plots were
generated using Ibidi Chemotaxis PlugIn.
1(https://imagej.nih.gov/ij/)
Three-Dimensional Spheroid Migration
Assay
Cells were seeded at 5 × 103 cells per well in low adherence
round bottomed 96 well plates (Nunc) in full media, serum-
free HSPG (Sigma) only supplemented media or serum free
HSPG/FGF2 supplemented media. After spheroid formation, the
supernatant was replaced with a mixture of collagen (Sigma),
DMEM (Sigma) growth medium for the high-grade cell lines
or Ham’s F-10 (1X) (Gibco) for the low-grade cells. 1M sodium
hydroxide (NaOH) (Sigma) was added to initiate collagen
polymerization. Each well was treated with a predetermined
inhibitor concentration orDMSO (Sigma) in at least three repeats
and separate experiments. Images were taken at 0, 24, 48, and
72 h to monitor spheroid invasion and migration using the
EVOS Cell Imaging System (Advanced Microscopy Group) at 4x
magnification. ImageJ was used to analyse the images. An overall
migration index (MI) was calculated, as previously described by
Cockle et al. (13).
Statistical Analysis
Independent unpaired t-tests were used to analyse the data from
the cell migration and 3D invasion assays. Immunofluorescence
was analyzed using Image J. Microsoft Excel was used to
calculate CTCF to determine the FGFR1 and pFGFR1 expression
in the cell lines. For the TMA generated data, a Pearson’s
chi squared test was conducted to investigate the association
between high or low FGFR1 expression with tumor grade,
location, tumor type, gender, and age using GraphPad Prism.
Both the dichotomized manual and computerized IHC scores
were used. P < 0.05 was considered statistically significant. For
analysis of the pFGFR1 localization TMA data Fisher’s exact test
was used.
RESULTS
FGFR1 Expression and pFRGR1
Localization Is Associated With Tumor
Grade and Malignancy
The purpose of the TMA analysis here was to confirm FGFR1
expression at the protein level and to validate clinical relevance of
FGFR1 expression and to investigate pFGFR1 expression levels.
Both adult and pediatric gliomas were included in the TMA.
Eight TMA cores were excluded because there was insufficient
tissue present to analyse. Using manual and computerized
scores there were clear differences in staining intensity and
percentage of cells stained indicating varying expression levels
for FGFR1 and localization for pFGFR1 (Figure 1A). Apart
from membranous labeling cytoplasmic and extracellular FGFR1
staining was also observed (Figure 1B). The ages were divided
into childhood and young adult (i.e., up to 25 years old), adult
(26–60 years old), and elderly populations (over 60 years old).
There was significantly low FGFR1 expression in childhood
and young adulthood tumors than the other age groups
(p = 0.04). There was a significant correlation between high
FGFR1 expression in the cerebrum compared to the cerebellum.
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FIGURE 1 | FGFR1 levels vary in tumor tissue samples from patients as determined by IHC. (A) Scanned high resolution image of the TMA stained for FGFR1 and
pFGFR1. Different intensities of antibody labeling were observed as indicated by brown staining. (B) Examples of strong and weak staining in TMA cores at low and
high magnification. Membranous and cytoplasmic labeling was observed. Top core shows a representative sample for negative stain (tuberculous inflammation) or
normal cerebellar tissue; the middle core represents a sample from a pediatric astrocytoma grade 2 and the bottom an example of a high grade pediatric glioma
(Individual cores × 10; magnified examples × 40). Arrows indicate staining patterns. m = membranous; c = cytoplasmic; e = extracellular.
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TABLE 1 | TMA results for FGFR1 expression reveal associations of FGFR1 expression levels with age, tumor location and malignancy.
Manual analysis FGFR1 Digital analysis
Clinical
characteristic
Low FGFR1
expression
(n = 46)
High FGFR1
expression
(n = 50)
p-value Low FGFR1
expression
(n = 53)
High FGFR1
expression
(n = 43)
p-value
Age p = 0.04 p = 0.13
25 and under 12 (26.1%) 4 (8.0%) 12 (22.6%) 4 (9.3%)
26–60 29 (63.0%) 42 (84.0%) 35 (66.0%) 36 (83.7%)
Over 60 5 (10.9%) 4 (8.0%) 6 (11.4%) 3 (7.0%)
Sex p = 0.99 p = 0.51
Male 24 (52.2%) 26 (52.0%) 26 (49.1%) 24 (55.8%)
Female 22 (47.8%) 24 (48.0%) 27 (50.9%) 19 (44.2%)
Location P < 0.0001 p = 0.02
Cerebrum 33 (71.7%) 50 (100.0%) 42 (79.2%) 41 (95.3%)
Cerebellum 13 (28.3%) 0 (0.0%) 11 (20.8%) 2 (4.7%)
Tumor type p = 0.89 p< 0.001
Benign 11 (23.9%) 11 (22.0%) 19 (35.8%) 3 (7.0%)
Malignant 29 (63.0%) 31 (62.0%) 27 (50.9%) 33 (76.7%)
Unknown 6 (13.0%) 8 (16.0%) 7 (13.2%) 7 (16.3%)
TABLE 2 | FGFR1 expression is associated with tumor grade in astrocytomas, with high expression found in grade 2 tumors.
Manual analysis FGFR1 astrocytomas only Digital analysis
Clinical
characteristic
Low FGFR1
expression
(n = 12)
High FGFR1
expression
(n = 20)
p-value Low FGFR1
expression
(n = 8)
High FGFR1
expression
(n = 24)
p-value
Age p = 0.77 p = 0.46
25 and under 2 (16.7%) 2 (10.0%) 1 (12.5%) 3 (12.5%)
26–60 8 (66.7%) 16 (80.0%) 5 (62.5%) 19 (79.2%)
Over 60 2 (16.7%) 2 (10.0%) 2 (25.0%) 2 (8.3%)
Sex p = 0.26 p = 0.40
Male 6 (50.0%) 14 (70.0%) 6 (75.0%) 14 (58.3%)
Female 6 (50.0%) 6 (30.0%) 2 (25.0%) 10 (41.7%)
Location P = 0.06 p = 0.40
Cerebrum 10 (83.3%) 20 (100.0%) 8 (100.0%) 22 (91.7%)
Cerebellum 2 (16.7%) 0 (0.0%) 0 (0.0%) 2 (8.3%)
Tumor grade p = 0.90 P = 0.02
1 2 (16.7%) 2 (10.0%) 2 (25.0%) 2 (8.3%)
2 4 (33.3%) 8 (40.0%) 1 (12.5%) 11 (45.8%)
3 2 (16.7%) 2 (10.0%) 0 (0.0%) 4 (16.7%)
4 3 (25%) 5 (25.0%) 5 (62.5%) 3 (12.5%)
Unknown 1 (8.3%) 3 (15.0%) 0 (0.0%) 4 (16.7%)
Patient samples obtained from the cerebrum had higher FGFR1
expression (p < 0.0001) than the cerebellum as determined
by manual scoring and digitized scoring (p = 0.02) (Table 1).
There was a significant positive association between malignancy
and FGFR1 expression. Malignant tumors had significantly high
FGFR1 expression compared to benign tumors by digital analysis
(p < 0.001; Table 1). There was also significantly high FGFR1
expression in grade 2 tumors (p = 0.02) indicative of a role
in tumorigenesis and disease progression (Table 2). Table 3
summarizes data obtained for the normal controls. We observed
two distinct protein localizations of pFGFR1, cytoplasmic and
membranous; there was a significant over-representation of
membranous staining in the malignant cases (38%) compared
to the benign (9%). Additionally, for the negative cases there
was an overrepresentation of no staining in the benign (68%)
compared the malignant (42%) (p = 0.024). There was an
over-representation of negative staining in grade one compared
with higher grades. Additionally, membranous staining was
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TABLE 3 | Data analysis of FGFR1 expression in normal controls does not reveal an association of FGFR1 expression.
Manual analysis FGFR1-controls Digital analysis
Clinical
Characteristic
Low FGFR1
expression
(n = 2)
High FGFR1
expression
(n = 6)
p-value Low FGFR1
expression
(n = 3)
High FGFR1
expression
(n = 5)
p-value
AGE
25 and under 0 (0.0%) 3 (50.0%) N/A 0 (0.0%) 3 (60.0%) P = N/A
26–60 2 (100.0%) 3 (50.0%) 3 (100.0%) 2 (40.0%)
Over 60 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
SEX
Male 0 (0.0%) 1 (16.7%) p = 0.54 0 (0.0%) 1 (20.0%) P = 0.41
Female 2 (100.0%) 5 (83.3%) 3 (100.0%) 4 (80.0%)
LOCATION
Cerebrum 1 (50.0%) 2 (33.3%) P = 0.67 2 (66.7%) 1 (20.0%) P = 0.19
Cerebellum 1 (50.0%) 4 (66.7%) 1 (33.3%) 4 (80.0%)
Subcellular pFGFR1 expression association.
TABLE 4 | Data analysis of subcellular pFGFR1 expression reveals association
with malignancy.
Malignant Benign p-value
Membranous 23 (38%) 2 (9%) 0.024
Cytoplasmic 12 (20%) 5 (23%)
Negative 25 (42%) 15 (68%)
pFGFR1 expression associated with grade.
TABLE 5 | Data analysis of subcellular pFGFR1 expression reveals association
with grade.
Grade 1 Grade 2 Grade 3 p-value
Negative 6 (100%) 3 (25%) 1 (20%) 0.010
Cytoplasmic 0 (0%) 3 (25%) 0 (0%)
Membranous 0 (0%) 6 (50%) 4 (80%)
significantly associated with higher grade cases (p = 0.010)
(Tables 4, 5).
Low Grade Pediatric Gliomas
Predominantly Express BRAF Fusion but
Are FGFR1 Wild Type
The BRAF fusion was present in 4 of 5 (80%) patient-derived cell
cultures of pLGG (IN1520, IN1591, IN2017, and IN2688), all of
which expressed the KIAA1549-BRAF 15-9 fusion supporting a
true representation of high BRAF frequency common to pLGGs
in our in vitromodels. Themedian CT value for the 15-9 fusion in
these 4 samples was 36.71 and 17.56 for GAPDH. The remaining
pLGG sample, IN2356, did not express any of the 3 KIAA1549-
BRAF fusions. None of the cell lines had FGFR1 mutations in the
investigated mutational hotspots.
Low Grade and High Grade Pediatric
Gliomas Exhibit Different Migratory
Phenotypes in 2D and 3D
We firstly wanted to ascertain if a panel of rare low grade patient-
derived cell lines had the ability to migrate in a 2D and 3D
environment and confirm migration in the two pediatric HGG
cell lines as previously described (13), since cell migration is
a prerequisite for tumor cell invasion and tumor recurrence.
Under FCS-supported growth conditions we noted that all
cell lines had distinct cell morphologies in in vitro cultures
highlighting inter-tumoral heterogeneity among these tumors
(Figure 2A). Our random 2D migration study revealed that all
cell lines possessed distinct migratory abilities (Figures 2B–D).
In 2D random migration velocity values ranged from 0.06 to
0.12 µm/min (pLGG cell lines) and 0.1 and 0.24 µm/min
(KNS42 and SF188). We also noted differences in the ability to
travel with directional persistence (distance traveled over time).
We observed values for distance traveled within 72 h of 23.6,
50.7, 61.4, 63.7, and 118.7µm for IN1520, IN2688, IN1591,
IN2017, and IN2356 and 37.2 and 122.7µm for KNS42 and
SF188 (Figure 2D). Interestingly, the velocity values obtained
for the pediatric LGG cell lines were similar within this group
and approaching the velocity observed for the high-grade cell
line KNS42. Directionality varied more among the pediatric
LGGs with values on a whole greater than those obtained
for KNS42. Among the pLGGs IN2356 exhibited the greatest
migratory activity, which was the cell line that did not have the
BRAF mutation.
We were able to generate spheroids for 3D migration
assays for all cell lines investigated (Figures 3A–C). We
firstly noted that the generated pLGG spheroids were much
smaller than the pHGG spheroids which is attributable to
low proliferative rates in the pLGGs, also observed in routine
tissue culturing. Interestingly, in the 3D migration assays all
LGGs migrated/invaded into the collagen matrix as efficiently
as the HGGs, with all migrating at a greater rate than KNS42
(Figures 3B,C). The MI indexes for the migration front were
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FIGURE 2 | Low and pHGGs are able to migrate in a 2D environment as assessed by random cell migration. (A) Five pLGGs and 2 pHGG cell lines were used in this
study. All cell lines were adapted to tissue culture and exhibited distinct morphologies. Scale bar = 1000 microns. SF188 and KNS42 magnification x 40.
(B) Diagrams to illustrate random migration and directionally persistent migration. According to Petrie et al. (17), directionality is defined as the displacement divided by
the total path length of the cell. If a cell is migrating more randomly, directionality decreases and vice versa. (C) Rose plots graphs generated for each cell line from
individual cells after imaging of random cell migration observed over 72 h highlighting migratory ability among the cell lines. (D) Graphic representation of random cell
migration of 2 HGGs and the five pLGGs as measured by velocity and distance traveled.
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FIGURE 3 | Low and HGGs are able to migrate/invade in a 3D environment as assessed by spheroid migration/invasion assays in collagen. (A) Diagram illustrating
the measuring zones for establishing migration in 3D. Two zones are measured, the invasion front and invasion edge. Unfilled cell cartoons indicate single cells with
potentially increased migratory activity supporting advanced migration/invasion into the collagen as previously observed. (B) Representative EVOS brightfield
microscopy images for spheroids and migratory cells of the individual cell lines over 72 h. After 72 h all cell lines had migrated/invaded into the collagen. Also shown is
a panel of enlarged images for the same cell lines to highlight morphological features of cell migration/invasion of the cell lines in 3D environments. Arrows indicate
migrating/invading cells. Scale bar= 1,000 microns. (C) Migration/invasion in 3D was measured and expressed as migration indexes (MI) for both the invasion front
and edge. Graphs illustrate results at three different time points over 72 h.
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FIGURE 4 | Low and high grade pediatric gliomas exhibit varying levels of FGFR1 and pFGR1. (A) Cell lines were assessed for FGFR1 and pFGFR1 levels by
immunofluorescence intensity values after stimulation with FGF2. Low grade gliomas exhibited higher levels of both FGFR1 and pFGFR1 than high grade gliomas.
(Continued)
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FIGURE 4 | Nuclear, cytoplasmic, and membranous localization was observed for pFGFR1 in the cell lines. Green—FGFR1 or pFGFR1 antibody; scale bar= 50
microns. SF188 is shown as a representative example of protein localization in HGGs and IN2688 as a representative example for LGGs. Only FGFR1 or pFGFR1
fluorescence staining patterns are shown to highlight the location of the proteins within the cells. Arrows indicate protein localizations in the cell lines SF188 and
IN2688 as representative examples. Note that the camera settings were the same for the cell lines within unstimulated and stimulated groups to allow comparison of
protein levels, which is illustrated in the differences in fluorescence levels of SF188 and IN2688 depicted here. (B) In 3D spheroids FGFR1 and pFGFR1 levels were
also detected in the cytoplasm and membranous locations. Top: FGFR1 expression and localization after stimulation with FGF2. Bottom: pFGFR1 expression after
stimulation with FGF2. (C) Graphic representation of protein levels in spheroids is shown. The spheroids had been stimulated with FGF2 and were fixed after 72 h. The
panel of images shows FGFR1 and pFGFR1 expression after stimulation with FGF2 in SF188, KNS42, IN1520, and IN2688 with membranous and cytoplasmic
localization as indicated by the arrows (x 20 magnification); scale bars 100–300 microns.
0.17, 0.2, 0.24, 0.26, and 0.3 for IN2688, IN2356, IN1520, IN1591,
and IN2017 and 0.09 and 0.32 for KNS42 and SF188. Migration
indexes for the migration edge of 0.28, 0.31, 0.35, 0.4, and
0.54 were obtained for IN2688, IN2356, IN1520, IN1591, and
IN2017 and 0.13 and 0.56 for KNS42 and SF188 (Figure 3C).
Slight morphological changes over time were observed for the
cells migrating away from the original core. The migrating cells
in IN1591 emanated from the core in a sheet-like manner.
A similar pattern was observed in IN2688 but with more
rounded cells. IN2017 consisted of tiny chains and streams of
cells extending from its core, suggesting a mixture of chain
and stream migration. IN2356 had appendages and streams
emanating from the core. In IN1520, there were single and
rounded cells detached from the core which could indicate
prominent single cell migration rather than clustered migration
in addition to string-like protrusions (Figure 3B). As previously
described SF188 migrated in a spike like manner with many
cells arranged in chains, whereas KNS42 produced cell sheets
expanding into the surrounding collagen (13) (Figure 3B).
Pediatric LGG and HGG Exhibit Varying
Levels of FGFR1 and Phosphorylated
FGFR1 After Stimulation With FGF2
We went on to investigate the relationship of migratory activity
and FGFR1 expression and activity, given that FGFR1 mutations
have been recently identified in pediatric gliomas (5) and we
had also determined associations of FGFR1 levels and pFGFR1
localization and various clinicopathologic parameters in our
TMAs. We first carried out immunofluorescence assays on all
cell lines to determine FGFR1 and pFGFR1 levels. We chose
this methodology over Western blotting as it proved difficult to
obtain the protein levels needed for SDS-PAGE electrophoresis
from cell extracts. Serum-free medium supplemented with FGF2
was chosen to determine cell response and protein localization to
stimulation with ligand to assess cellular response to stimulation
with the preferred ligand FGF2. There were varying levels of
FGFR1 and pFGFR1 and protein localization after stimulation
with FGF2 between cell lines. We demonstrated the highest
FGFR1 levels in IN2356, followed by IN2688, IN1591, IN2017,
and IN1520. SF188 had higher FGFR1 levels than KNS42.
Interestingly, the highly migratory cell line IN2356 had the
highest levels of FGFR1 and was also the only cell line with
no BRAF mutation. A similar observation was made for the
levels of pFGFR1 for the pediatric LGG; protein levels in SF188
and KNS42 did not differ but were significantly lower than the
protein levels observed in the pediatric LGG. We also observed
distinct protein localizations: nuclear and cytoplasmic for total
FGFR1 and nuclear, cytoplasmic and membrane associated for
phosphorylated FGFR1 (Figure 4A, Supplemental Figure 1).
We also analyzed FGFR1 and pFGFR1 levels in spheroids
prepared for immunohistochemistry (IHC) derived from IN1520
and IN2688 as well as SF188 and KNS42, which were the cell lines
that had generated the largest spheroids we were able to process
for IHC. We were able to demonstrate specific FGFR1 and
pFGFR1 staining in the spheroids; in spheroids grown inmedium
supplemented with serum (FCS) all cell lines expressed FGFR1;
we only detected pFGFR1 in one cell line, SF188. FGFR1 was
localized in the cytoplasm, whereas we noted both cytoplasmic
and membranous labeling in the pFGFR1 stain (data not shown).
In spheroids grown in FGF2 supplemented-serum free medium,
FGFR1 was again detected in all cell lines; this time, pFGFR1
was present in all cell lines examined (Figures 4B,C) indicating
FGFR1 activation after stimulation with ligand.
Cell Migration Is Promoted by FGFR1
Stimulation With FGF2 in Some Pediatric
Glioma Cell Lines and Affects
Anti-migratory Activity of FGFR1 Inhibitors
To assess a potential role for FGFR1 signaling in cell migration we
replaced whole medium containing FCS with serum free medium
supplemented with either HSPG only or with FGF2/HSPG as
ligand for FGFR1 signaling. FGFR1 stimulation with FGF2 under
serum-free conditions promotedmigration in the pLGG cell lines
IN1591, IN2017, and IN2356 and in the pHGG cell line KNS42
and in terms of directionality in KNS42 in 2D (Figures 5A,B)
as assessed against cells stimulated with HSPG (hep) only.
Phenotypically we observed dramatic changes in cell morphology
in some of the cell lines, especially KNS42 where large, flattened
cells became elongated and thinner and in the pediatric LGGs
IN2017, IN2356 and IN2688 where cells with a similar cell
morphology to KNS42 adopted a mesenchymal phenotype with
a pronounced cell front and longer cell protrusions in response
to stimulation with FGF2 in keeping with a more migratory
phenotype (Figure 5A, Supplemental Figure 2).
We next asked if FGFR1 driven migration could be
inhibited by the activity of three different FGFR1 inhibitors
differing in their specificity against FGFRs. We observed
anti-migratory effects with the inhibitors Ponatinib (Pona),
BGJ398 (BGJ), and SSR128129E (SSR) at pre-determined
anti-migratory concentrations. In 2D random cell migration,
SF188 velocity was affected by Ponatinib and SSR128129E
and all three inhibitors reduced cell velocity in KNS42.
IN1591 was affected by treatment with SSR128129E and
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FIGURE 5 | Cell migration is stimulated in serum free conditions after the addition of FGF2 and migratory activity is inhibited in some cell lines after addition of FGFR1
inhibitors in 2D random cell migration. (A) Stills of live cell imaging of various low and high grade pediatric cell lines after 72 h reveal anti-migratory effects of inhibitors.
Colored lines indicate migration tracts of individual cells. Inset images show traces of individual representative cells for enhanced visualization of cell morphology. All
images original magnification x 20. (B) Graphic representation of migration in 2D under serum-free conditions after the addition of FGF2 by pLGGs and HGGs. Results
for both velocity and directionally persistent migration as indicated by distance traveled are shown. *denotes p < 0.05; **p < 0.01.
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FIGURE 6 | Cell migration is stimulated in serum free conditions after the addition of FGF2 and migratory activity is inhibited in some cell lines after addition of FGFR1
inhibitors in 3D invasion assays. Representative images of spheroids allowed to migrate under serum free conditions and with the addition of FGF2 indicate the
inhibitory activity of various FGFR1 inhibitors after treatment with inhibitors (Ponatinib, SSR and BGJ). Examples are shown for the HGGs and LGGs at beginning of
the experiment and after 72 h (x 40). Also shown are images of the spheroid at higher magnification to allow visualization of morphological features of migratory cells
close to the spheroid edge (labeled enlarged) as indicated by the arrows.
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FIGURE 7 | Graphic representation of migration by pLGGs and HGGs in 3D under serum-free conditions after the addition of FGF2. As a control, spheroid migration
under serum free conditions with HSPG only are also shown. FGF2-stimulation was in combination with HSPG. Results are shown for both the effect of the inhibitors
on the migration front (Top) and edge (Bottom). *Denotes *p < 0.05; **p < 0.01; ***p < 0.001.
BGJ398. Directionality was reduced by all three inhibitors
in only the two high grade gliomas, SF188 and KNS42
(Figures 5A,B).
In the 3D migration assays, we also observed morphological
changes in the migratory cells, especially in KNS42, where we
observed elongated protrusions and in SF188 rounded individual
cells and in IN1591 spheroids with more pronounced string-
like protrusions and IN2688 with more prominent cell sheets
(Figure 6, Supplemental Figure 3). Overall, there were more
noticeable effects on cell migration of the migration front
than the migration edge after stimulation with FGF2 under
serum-free conditions; FGF2 induced enhanced migration in
SF188 and KNS42 and pLGG IN1591 and IN2688, which
were the cell lines with clear morphological changes (Figure 6,
Supplemental Figure 3). In the migration edge only the pHGG
cell lines were affected by FGFR1 stimulation as indicated by
an increase in MI values (Figure 7). Reduced migration front
indexes were recorded after addition of Ponatinib (KNS42) and
Ponatinib and BGJ398 (SF188), and in IN1591 and IN1520
with Ponatinib only. Interestingly, in two low grade cell lines,
IN2017 and IN2356, there was a trend of inhibitors to enhance
cell migration (Figure 7). For the migration edge, decreased
migration was observed in SF188 with BGJ398 and in KNS42
with Ponatinib, as well as in IN1591 and IN1520 with Ponatinib.
As for the migration front there were trends in IN2017,
IN2356, and IN2688 for increased cell migration after treatment
with the three inhibitors (Figure 7). Markers for apoptosis
(cleaved caspase 3) remained unchanged in the spheroids
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TABLE 6 | Ki67 expression in FGF2-stimulated spheroids without and with
inhibitor treatment.
IN2688 IN1520 KNS42 SF188
Ki67 FGFR1 stim Low High High High
Ki67 FGFR1 stim +Ponatinib Low High High High
Ki67 FGFR1 stim + SSR Low Low Low Low
Ki67 FGFR1 stim + BGJ Low High Low High
TABLE 7 | Cleaved caspase 3 expression in FGF2-stimulated spheroids without
and with inhibitor treatment.
IN2688 IN1520 KNS42 SF188
CC3 FGFR1 stim Low Low Low High
CC3 FGFR1 stim +Ponatinib Low Low Low High
CC3 FGFR1 stim + SSR Low Low Low High
CC3 FGFR1 stim + BGJ Low Low Low High
tested, confirming that the observed inhibitor effect resulted
from anti-migratory activity and not cytotoxicity; proliferation
(Ki67) was affected after treatment with SSR128129E in IN1520,
KNS42, and SF188 and in KNS42 after treatment with BGJ398
(Tables 6, 7).
DISCUSSION
Brain tumors are the most common solid tumors of childhood
with high mortality rates highlighting the clinical importance
of exploring new therapeutic targets to combat this devastating
disease (18, 19). Identification of potential targets must take into
account the need for combination treatments to avoid resistance
to inhibition of specific kinase signaling pathways and one of
these potential targets is FGFR1. Following recent reports of
recurrent FGFR1mutations in pediatric gliomas and known roles
for FGFR1 in invasion in other cancer types, we firstly wanted
to determine clinical relevance of FGFR1 expression. Our TMA
results revealed increased FGFR1 expression inmalignant tumors
in comparison to benign tumors. We also recorded an overall
finding that associated high FGFR1 levels with low grade tumors
suggesting a role of FGFR1 in tumorigenesis. We also found
evidence of an association of activated FGFR1 when localized
in the cell membrane with malignancy and tumor grade (2 and
3). This may be indicative of a role of activated FGFR1 and
tumor progression. In the subset of pediatric and young adult
samples in this cohort we found a negative association of FGFR1
expression and age; based on a small sample size these results
must be validated by establishment of large scale TMAs. We next
investigated the potential for cell migration in low and high grade
pediatric gliomas as a prerequisite for disease progression and
recurrence and, next, assessed the role of FGFR1 in cell migration
and invasion for chemotherapeutic intervention (20–23). This
is a novel therapeutic approach, targeting a hallmark feature
of brain tumor pathogenesis and has to our knowledge not
been investigated in pediatric gliomas beyond genomic analyses.
We describe for the first time the migratory behaviors of rare
low grade pediatric patient cell lines. All cell lines displayed a
specific migratory phenotype and this was largely independent
of glioma grade. This demonstrates differences in migratory
behaviors amongst tumors of the same grade, highlighting
that each tumor is unique with specific cell migration and
invasion patterns. Targeting cell migration and invasion with
treatment should reflect this uniqueness particularly when
considering combination treatment with inhibitors targeting
other signaling pathways.
Both pediatric LGG and HGGs possessed varying levels of
FGFR1 and pFGFR1 in 2D monolayers and cells maintained
within 3D spheroids. The ability of pediatric LGGs to form
spheroids in in vitro systems is a novel observation and
indicates the potential of using this model for further studies
on tumorigenesis and applicability in drug screens. Interestingly,
in pediatric LGGs, FGFR1 levels were higher than in HGGs
in 2D monolayers but in 3D environments activated FGFR1
levels were higher in the highly migratory SF188 suggesting
differential roles of FGFR1 signaling among low and high grade
gliomas depending on the microenvironment. In FGFR-FGF2
stimulation assays we also determined that some of the cell
lines responded to stimulation with morphological changes from
a rounded to a more elongated mesenchymal phenotype and
potentially enhancedmigration. There was an increase in velocity
and reduction in directionality in the cell lines apart from
IN2688. Reduced directionality in the cell lines may indicate
a loss of cell polarity following FGFR1 stimulation (24, 25).
Previous studies have demonstrated FGFR1 activation caused a
loss of cell polarity in breast cancers (26). In 3D, the pediatric
HGG both had increased migration indexes in HSPG/FGF2
compared to HSPG only controls which suggested pro-migratory
effects of FGFR1mirroring the observed protein expression levels
of activated FGFR1. In contrast, the pediatric LGG were mixed in
their responses to FGFR1 stimulation with increased or decreased
migration as well as morphological changes observed in the
spheroids with increased numbers of migrating cells highlighting
the heterogeneity among low grade tumors.
Treatment with Ponatinib, a multi-targeted tyrosine
kinase inhibitor, BGJ398, a pan-FGFR inhibitor with
VEGFR activity, and SSR128129E, a highly specific FGFR1
inhibitor induced different responses in the cell lines (27–
29). The greatest overall reduction seen across all inhibitors
was with BGJ398, which suggests one of its other targets
(i.e., VEGFR2 and/or FGFR2-4) may contribute to cell migration
as well as FGFR1 indicating the involvement of other kinase
signaling. We propose to include BGJ398 in future in vitro
treatment combination studies targeting BRAF in patients with
BRAF mutations to investigate potential new therapeutic
avenues. We also suggest further testing of BGJ398 in
combination and as stand-alone in BRAF wildtype/FGFR1
mutation patients.
Differences were seen in FGFR1 expression at the protein
level between pediatric LGG and HGG. Differences in expression
between tumor grades have been well established in adult gliomas
(30). However, our immunofluorescence results indicated higher
FGFR1 expression in pediatric LGG thanHGG, which is opposite
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to the observations in adult gliomas supporting pediatric gliomas
to be biologically distinct from adult gliomas (31).
We demonstrate migratory phenotypes of low grade pediatric
astrocytoma cells in a 2D and 3D environment, varying
expression of FGFR1 and its activated form at the protein level
and finally distinct responses to FGFR1 inhibition. We also
observed varying anti-migratory effects with the inhibitors used
on pediatric HGG. Reports from other cancer types targeted
with FGFR1 inhibitors support the notion that inhibitors do
not have equivalent efficiency varying from one tumor type
and drug family to another suggesting the FGFR alterations
have different biological meanings (32). Inhibitor effects appear
to be cell line specific, highlighting the need for personalized
treatment of pediatric gliomas. Although our study did not
reveal mutations in the reported hotspots additional published
mutations should be analyzed in our sample set and we also
hypothesize that FGFR1 overexpression alone can drive tumor
progression in pediatric gliomas, which needs to be explored in
further studies.
There is compelling evidence that FGFR1 signaling has
a significant role in glioma tumorigenesis and progression.
FGFR1 expression is positively associated with more invasive
and malignant adult gliomas and thus positively associated with
poorer prognoses (30). Given the lack of treatment options for
relapsed and refractory pediatric HGGs, future work should focus
on investigating FGFR1 signaling as a chemotherapeutic target
for this patient group (31, 32). There is scope that targeting
FGFR1 signaling on its own or in combination has the potential
to improve prognosis. Future studies must address the role of
FGFR1 in pediatric gliomas and its effect on the different tumor
hallmarks is needed (33, 34).
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Supplemental Figure 1 | Immunofluorescence images for SF188 and IN2688
labeled for FGFR1 (green), pFGFR1 (green), actin (phalloidin, red), and DNA (DAPI,
blue) and merged images of the three channels. The panels are presented in the
same order as shown for the images in Figure 4. Scale bar = 50microns.
Supplemental Figure 2 | Graphic representation of morphological features
observed in 2D cultures in response to stimulation with FGF2 ligand and treatment
with inhibitor. Morphological changes in cell size were observed after stimulation
with FGF2 and treatment with inhibitor as indicated.
Supplemental Figure 3 | Graphic representation of morphological features
observed in migratory cells of 3D spheroid cultures in response to stimulation with
FGF2 ligand and treatment with inhibitor. Morphological changes in migrating cells
away from original spheroid cores were observed after stimulation with FGF2 and
treatment with inhibitor.
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